Viewing nowCombinationSiglip Duo Tablet 50/850 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.

MFDS item code 202200030 · Approved 2022.01.03 · Insurance code 628902100
Improvement of glycemic control in type 2 diabetes mellitus
This drug is used to help control blood sugar levels in patients with type 2 diabetes in conjunction with diet and exercise therapy. It can be used in patients who have not previously taken diabetes medication or have difficulty controlling blood sugar with monotherapy. It is also useful when blood sugar control is insufficient with either metformin or sitagliptin monotherapy or when replacing combination therapy of the two drugs. It can be combined in patients who have difficulty controlling blood sugar with the combination of metformin and sulfonylurea, or metformin and thiazolidinedione. If blood sugar control remains insufficient after insulin and metformin combination therapy, it can be used with insulin to improve blood sugar control. This medication effectively improves blood sugar control in patients with type 2 diabetes when used with various therapeutic methods.
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients in whom this medicine should not be used). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral hypoglycemic agent to this medicine. Any change in treatment for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom this medicine should not be used).
This medication contains sitagliptin and metformin and is used for the treatment of diabetes. Firstly, serious allergic reactions may occur while taking this drug, so if symptoms such as skin rash or difficulty breathing arise, you should stop taking it immediately and consult your doctor. Additionally, this medication may cause acute pancreatitis, which is inflammation of the pancreas, so if abdominal pain, vomiting, or severe abdominal discomfort occurs after taking the drug, you should promptly visit a hospital. The metformin component can cause lactic acidosis, a rare but serious metabolic disorder, so it should not be taken in cases of decreased kidney function, dehydration, severe infection, or heart problems. This drug should not be given to patients with moderate to severe kidney dysfunction, acute heart failure, or acute myocardial infarction, and should be discontinued for a certain period before and after tests using iodinated contrast agents. It is safer not to use this medication in pregnant or nursing women, and in children and adolescents under 18 years of age. During treatment, symptoms of hypoglycemia due to excessively low blood sugar may occur, so do not skip meals and take the medication regularly, and be cautious when used with other antidiabetic agents as the risk of hypoglycemia may increase. Regular monitoring of kidney function and blood tests should be performed while taking this medication, and periodic checks of vitamin B12 levels are recommended. Excessive drinking or acute or chronic alcohol intake can increase the risk of lactic acidosis, so it should be avoided. If surgery is planned, the medication should be discontinued 48 hours prior to surgery and resumed only after kidney function has been confirmed to be normal post-surgery. Finally, this medication may interact with other drugs, so inform your healthcare provider about all medications being taken, and always consult before starting or stopping any new medications.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, severe and disability-associated arthralgia, vesicular pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, dermatitis, anorexia, weight loss, dyspnea, unstable angina, dizziness, acute renal failure, decreased appetite, gastrointestinal disturbances, itching
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air ingress, ideally between 1 and 30 degrees Celsius. Storing it this way helps maintain the medication's effectiveness and prevents degradation.
Pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.